Back to top
more

BioDelivery Sciences International, Inc. (BDSI)

(Delayed Data from NSDQ)

$4.84 USD

4.84
695,323

+0.08 (1.68%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.85 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Champions Oncology (CSBR) Q3 Earnings: What's in Store?

During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.

What's in the Cards for Novavax (NVAX) This Earnings Season?

Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.

What's in the Cards for Aeterna (AEZS) This Earnings Season?

Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.

Endo (ENDP) Q4 Earnings & Revenues Beat Estimates, Shares Up

Endo's (ENDP) earnings and revenues top expectations in the fourth quarter.

Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018

Amicus (FOLD) reports wider-than-expected loss in 2018, while revenues exceed estimates.

The Meet Group (MEET) to Report Q4 Earnings: What's in Store?

The Meet Group's (MEET) fourth-quarter 2018 results are expected to benefit from strong growth in video revenues.

Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat

Horizon Pharma's (HZNP) earnings and sales beat estimates in the fourth quarter of 2018.

Zacks.com featured expert Kevin Matras highlights: First, Clearfield, BioDelivery Sciences International, MGIC Investment and Kratos Defense & Security Solutions

Zacks.com featured expert Kevin Matras highlights: First, Clearfield, BioDelivery Sciences International, MGIC Investment and Kratos Defense & Security Solutions

Editas (EDIT) to Report Q4 Earnings: What's in the Cards?

Focus of Editas' (EDIT) fourth-quarter conference call is likely to be on its pipeline.

Jazz Pharma (JAZZ) Q4 Earnings & Sales Beat, Stock Up 8%

Jazz Pharmaceuticals (JAZZ) surpasses earnings and sales estimates in the fourth quarter and issues a solid outlook for 2019. Shares rise 8% in after-hours trading.

Swarup Gupta headshot

5 Affordable Breakout Stocks for Superlative Returns

Seeking breakout stocks is probably one of the most favored techniques among active investors.

What's in the Cards for Nektar (NKTR) This Earnings Season?

Nektar Therapeutics (NKTR) will report fourth-quarter results on Feb 28. Investors are expected to focus on pipeline progress.

Amgen Starts Phase III Enrollment for Heart Failure Drug

Amgen (AMGN) and partners started enrollment for the second phase III study of omecamtiv mecarbil, which is being developed for the potential treatment of heart failure with reduced ejection fraction.

What's in Store for Vericel (VCEL) This Earnings Season?

On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.

What's in Store for Teladoc's (TDOC) Q4 Earnings?

Teladoc's (TDOC) Q4 earnings might suffer high expenses, partly offset by rise in revenues.

bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y

bluebird (BLUE) reports narrower-than-expected Q4 loss. The pipeline progress looks encouraging.

BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline

BioMarin (BMRN) misses estimates for earnings and revenues in the fourth quarter. Shares decline in after-hours trading.

BioDelivery Sciences International (BDSI) Dips More Than Broader Markets: What You Should Know

In the latest trading session, BioDelivery Sciences International (BDSI) closed at $4.73, marking a -0.63% move from the previous day.

Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer

Agios' (AGIO) label expansion filing eyes an approval of Tibsovo for newly diagnosed acute myeloid leukemia patients with an IDH1 mutation. The drug also gets a priority review tag from the FDA.

Key Factors to Know Ahead of TransEnterix (TRXC) Q4 Earnings

TransEnterix (TRXC) is anticipated to witness robust top-line growth in Q4 on the back of multiple product developments.

Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q4

Ultragenyx (RARE) loss narrower than expected and sales beat estimates in the fourth quarter of 2018.

What's in Store for Sangamo (SGMO) This Earnings Season?

On Sangamo (SGMO) Q4 conference call, investors will look into genome editing development and gene regulation technology platform, used for inventing genomic therapies to address unmet medical needs.

What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the fourth quarter.

Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock

Agios' (AGIO) loss tops estimates in Q4. Its precision medicine Tibsovo receives the FDA nod and leads to significant year-over-year revenue growth.

Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates

Acorda (ACOR) rides high on earnings and revenue beat in Q4. The company plans the US launch of Inbrija in first-quarter 2019.